Analysts expect Boston Scientific Corporation (NYSE:BSX) to report $2.34 billion in sales for the current quarter, according to Zacks. Eight analysts have issued estimates for Boston Scientific’s earnings, with the lowest sales estimate coming in at $2.32 billion and the highest estimate coming in at $2.36 billion. Boston Scientific posted sales of $2.16 billion in the same quarter last year, which would indicate a positive year-over-year growth rate of 8.3%. The business is scheduled to announce its next earnings report on Thursday, April 26th.
On average, analysts expect that Boston Scientific will report full-year sales of $2.34 billion for the current year, with estimates ranging from $9.70 billion to $9.77 billion. For the next fiscal year, analysts anticipate that the company will post sales of $10.32 billion per share, with estimates ranging from $9.90 billion to $10.54 billion. Zacks Investment Research’s sales averages are a mean average based on a survey of research analysts that cover Boston Scientific.
Boston Scientific (NYSE:BSX) last announced its quarterly earnings data on Thursday, February 1st. The medical equipment provider reported $0.34 earnings per share for the quarter, meeting analysts’ consensus estimates of $0.34. The company had revenue of $2.41 billion for the quarter, compared to analyst estimates of $2.39 billion. Boston Scientific had a return on equity of 24.04% and a net margin of 1.15%. The firm’s revenue for the quarter was up 9.9% on a year-over-year basis. During the same quarter last year, the firm posted $0.30 EPS.
Boston Scientific (NYSE BSX) opened at $25.92 on Monday. The company has a quick ratio of 0.50, a current ratio of 0.72 and a debt-to-equity ratio of 0.58. The firm has a market capitalization of $35,590.00, a price-to-earnings ratio of 370.29, a price-to-earnings-growth ratio of 1.88 and a beta of 0.81. Boston Scientific has a fifty-two week low of $23.29 and a fifty-two week high of $29.93.
In other news, insider Valley Gold Master Fund L. Sun bought 408,006 shares of the company’s stock in a transaction on Tuesday, November 28th. The stock was bought at an average cost of $0.45 per share, with a total value of $183,602.70. Also, SVP David A. Pierce sold 5,152 shares of Boston Scientific stock in a transaction dated Tuesday, January 9th. The shares were sold at an average price of $27.00, for a total value of $139,104.00. Following the completion of the transaction, the senior vice president now directly owns 38,116 shares of the company’s stock, valued at $1,029,132. The disclosure for this sale can be found here. Insiders have sold a total of 161,464 shares of company stock valued at $4,253,617 over the last three months. Corporate insiders own 0.74% of the company’s stock.
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in BSX. Cerebellum GP LLC acquired a new position in Boston Scientific in the 4th quarter valued at about $126,000. Valeo Financial Advisors LLC acquired a new position in Boston Scientific in the 3rd quarter valued at about $138,000. Steward Partners Investment Advisory LLC acquired a new position in Boston Scientific in the 3rd quarter valued at about $139,000. Ironwood Investment Counsel LLC acquired a new position in Boston Scientific in the 3rd quarter valued at about $204,000. Finally, Perkins Capital Management Inc. acquired a new position in Boston Scientific in the 3rd quarter valued at about $204,000. 90.15% of the stock is owned by institutional investors.
Boston Scientific Company Profile
Boston Scientific Corporation is a developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. The Company offers its products by seven businesses: Interventional Cardiology, Cardiac Rhythm Management, Endoscopy, Peripheral Interventions, Urology and Pelvic Health, Neuromodulation, and Electrophysiology.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Boston Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific and related companies with MarketBeat.com's FREE daily email newsletter.